This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) Laps the Stock Market: Here's Why
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $70.56, moving +0.84% from the previous trading session.
Medtronic (MDT) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
Medtronic (MDT) closed at $69.97 in the latest trading session, marking a +0.78% move from the prior day.
The Zacks Analyst Blog Highlights Netflix, Honeywell, RTX, Medtronic and Eaton
by Zacks Equity Research
Netflix, Honeywell, RTX, Medtronic and Eaton are included in this Analyst Blog.
Top Stock Reports for Netflix, Honeywell International & RTX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc. (NFLX), Honeywell International Inc. (HON) and RTX Corporation (RTX).
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $71.96, moving -0.59% from the previous trading session.
Shockwave Medical (SWAV) Announces IVL Studies' Positive Results
by Zacks Equity Research
Shockwave Medical's (SWAV) latest announcement of two new publications validates the utility of IVL in complex nodular and eccentric calcium.
MDT or ESLOY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MDT vs. ESLOY: Which Stock Is the Better Value Option?
The 3 Widest Competitive Moats on Wall Street
by Andrew Rocco
Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.
Top Research Reports for Thermo Fisher Scientific, AMD & BP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), Advanced Micro Devices, Inc. (AMD) and BP p.l.c. (BP).
Medtronic (MDT) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $76.12, signifying a -0.04% move from its prior day's close.
Medtronic (MDT) to Launch Academic R&D Grants With New Pact
by Zacks Equity Research
Medtronic's (MDT) partnership will enable teachers to improve their skill set, boosting student opportunities to pursue STEM careers in corporate America.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic (MDT) on strong global expansion.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Medtronic (MDT) Gets CE Mark Approval for the New Simplera CGM
by Zacks Equity Research
Medtronic's (MDT) next-generation sensor Simplera receives CE Mark approval.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovator of neurovascular stroke technologies with 980% EPS growth is a buying opportunity
Why Is Medtronic (MDT) Down 2.6% Since Last Earnings Report?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Chevron, AstraZeneca, Netflix, Medtronic and Marvell Technology
by Zacks Equity Research
Chevron, AstraZeneca, Netflix, Medtronic and Marvell Technology are included in this Analyst Blog.
Top Research Reports for Chevron, AstraZeneca & Netflix
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), AstraZeneca PLC (AZN) and Netflix, Inc. (NFLX).
Medtronic's (MDT) Inceptiv Spinal Cord Stimulator Gets CE Mark
by Zacks Equity Research
Medtronic's (MDT) Inceptiv SCS System is the first Medtronic SCS device to offer a closed-loop feature that senses each person's unique biological signals.
MDT or PODD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MDT vs. PODD: Which Stock Is the Better Value Option?
Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Up (Revised)
by Zacks Equity Research
Strength across businesses and geographies, driven by execution, innovation, and improved underlying fundamentals contributes to Medtronic (MDT) Q1 revenues.
Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Strength across businesses and geographies, driven by execution, innovation and improved underlying fundamentals, contributes to Medtronic's (MDT) Q1 revenues.
Medtronic (MDT) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Medtronic (MDT) give a sense of how the business performed in the quarter ended July 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Medtronic (MDT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 8.11% and 1.71%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Medtronic (MDT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Medtronic (MDT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.